论文部分内容阅读
目的比较急性白血病化疗前后血浆组织因子(TF)和组织因子途径抑制物(TFPI)的变化,探讨其在在病情进展、疗效观察及预后判断中的价值。方法选择2011年1月～2011年10月32例急性白血病患者为研究对象,分别于化疗前及缓解期采用酶联免疫吸附法(ELISA)测定两组血浆TF和TFPI含量。同时选择同期健康体检者30例为正常对照组。结果化疗前,急性白血病组患者血浆TF和TFPI分别为(77.9±12.2)ng/L、(160.3±20.2)ng/ml,明显高于正常对照组的(32.6±2.8)ng/L、(132.8±12.5)ng/ml,差异均有统计学意义(P﹤0.05)。32例患者化疗2个疗程后,24例缓解,8例未缓解。缓解组患者血浆TF及TFPI含量较化疗前明显下降,差异有统计学意义(P﹤0.05);未缓解组患者血浆TF及TFPI含量与化疗前比较,差异无统计学意义(P﹥0.05)。结论血浆TF及TFPI含量对急性白血病患者的病情进展及治疗效果具有一定的预测价值。
Objective To compare the changes of plasma Tissue Factor (Tff) and Tissue Factor Pathway Inhibitor (TFPI) before and after the treatment of acute leukemia and to explore the value of TFPI in the progression of disease, the observation of curative effect and the prognosis. Methods Thirty-two patients with acute leukemia from January 2011 to October 2011 were selected as study subjects. Plasma TF and TFPI levels were measured by enzyme-linked immunosorbent assay (ELISA) before and during chemotherapy. At the same time select the same period, 30 healthy subjects were normal control group. Results Before chemotherapy, the plasma levels of TF and TFPI in patients with acute leukemia were (77.9 ± 12.2) ng / L and (160.3 ± 20.2) ng / ml, respectively, significantly higher than those in the control group (32.6 ± 2.8) ng / L and ± 12.5) ng / ml, the differences were statistically significant (P <0.05). After 32 courses of chemotherapy, 24 patients were relieved and 8 patients did not relieve. The levels of plasma TF and TFPI in remission group were significantly lower than those before chemotherapy (P <0.05). The plasma levels of TF and TFPI in non-remission group were not significantly different from those before chemotherapy (P> 0.05). Conclusion The plasma levels of TF and TFPI have some predictive value in the progression of patients with acute leukemia and the therapeutic effect.